English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

We would like to thank Drs. Szarvas, Olah, and Reis for their thoughtful and insightful comments regarding our recent publication on patients who initially present with muscle-invasive bladder cancer (“primary” MIBC) compared to patients with non-muscle-invasive bladder cancer (NMIBC) who unfortunately experience progression to MIBC (“secondary” MIBC). As this latter group account for only 15–20% of MIBC patients, such patients were underrepresented in the clinical trials from which guidelines for neoadjuvant chemotherapy were based.

“Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes